Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Kyverna Therapeutics presented updated Phase 1 data from the COMPARE trial for miv-cel in treatment-refractory rheumatoid arthritis at the EULAR 2026 Congress. The data showed that 66.6% of the six heavily pre-treated patients achieved ACR70 response by Week 36, with deep B-cell depletion and evidence of an immune reset.
Key figures
- Drug Name
- miv-cel (mivocabtagene autoleucel, KYV-101)
- Phase Of Trial
- Phase 1
- Acr70 response rate
- 66.6%
- Patient count phase1
- 6
- Median prior biologics failed
- 6.5
- Total patients treated to date
- 100
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.